D-Wave Quantum Completes Proof-of-Concept Project in Drug Discovery With Japan Tobacco's Drug Unit

MT Newswires Live2025-03-31

D-Wave Quantum (QBTS) and the pharmaceutical division of Japan Tobacco said Monday that they completed a joint proof-of-concept project adapting D-Wave's quantum computing technology and artificial intelligence for the drug discovery process.

The companies developed hybrid large language models that generated "more valid" molecules with a higher quantitative estimate of drug-likeness, compared with classical methods alone, they said.

Following the proof-of-concept project, Japan Tobacco's pharmaceutical division now plans to further advance development of quantum AI-driven drug discovery technology for molecular design, the companies said.

Price: 7.59, Change: +0.01, Percent Change: +0.15

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment